Literature DB >> 15992385

Evidence for increased expression of the vesicular glutamate transporter, VGLUT1, by a course of antidepressant treatment.

Rosa M Tordera1, Qi Pei, Trevor Sharp.   

Abstract

The therapeutic effect of a course of antidepressant treatment is believed to involve a cascade of neuroadaptive changes in gene expression leading to increased neural plasticity. Because glutamate is linked to mechanisms of neural plasticity, this transmitter may play a role in these changes. This study investigated the effect of antidepressant treatment on expression of the vesicular glutamate transporters, VGLUT1-3 in brain regions of the rat. Repeated treatment with fluoxetine, paroxetine or desipramine increased VGLUT1 mRNA abundance in frontal, orbital, cingulate and parietal cortices, and regions of the hippocampus. Immunoautoradiography analysis showed that repeated antidepressant drug treatment increased VGLUT1 protein expression. Repeated electroconvulsive shock (ECS) also increased VGLUT1 mRNA abundance in regions of the cortex and hippocampus compared to sham controls. The antidepressant drugs and ECS did not alter VGLUT1 mRNA abundance after acute administration, and no change was detected after repeated treatment with the antipsychotic agents, haloperidol and chlorpromazine. In contrast to VGLUT1, the different antidepressant treatments did not commonly increase the expression of VGLUT2 or VGLUT3 mRNA. These data suggest that a course of antidepressant drug or ECS treatment increases expression of VGLUT1, a key gene involved in the regulation of glutamate secretion.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15992385     DOI: 10.1111/j.1471-4159.2005.03192.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  27 in total

1.  Co-localization of corticotropin-releasing factor and vesicular glutamate transporters within axon terminals of the rat dorsal raphe nucleus.

Authors:  Maria Waselus; Elisabeth J Van Bockstaele
Journal:  Brain Res       Date:  2007-08-14       Impact factor: 3.252

2.  Targeting glial physiology and glutamate cycling in the treatment of depression.

Authors:  Gerald W Valentine; Gerard Sanacora
Journal:  Biochem Pharmacol       Date:  2009-04-17       Impact factor: 5.858

3.  A neuroprotective role for microRNA miR-1000 mediated by limiting glutamate excitotoxicity.

Authors:  Pushpa Verma; George J Augustine; Mohamed-Raafet Ammar; Ayumu Tashiro; Stephen M Cohen
Journal:  Nat Neurosci       Date:  2015-02-02       Impact factor: 24.884

Review 4.  Synaptic vesicle protein trafficking at the glutamate synapse.

Authors:  M S Santos; H Li; S M Voglmaier
Journal:  Neuroscience       Date:  2008-03-22       Impact factor: 3.590

5.  Nucleocytoplasmic export of HDAC5 and SIRT2 downregulation: two epigenetic mechanisms by which antidepressants enhance synaptic plasticity markers.

Authors:  I Muñoz-Cobo; M M Erburu; C Zwergel; R Cirilli; A Mai; S Valente; E Puerta; Rosa M Tordera
Journal:  Psychopharmacology (Berl)       Date:  2018-08-08       Impact factor: 4.530

Review 6.  Glutamatergic drive of the dorsal raphe nucleus.

Authors:  Mariano Soiza-Reilly; Kathryn G Commons
Journal:  J Chem Neuroanat       Date:  2011-04-27       Impact factor: 3.052

Review 7.  Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders.

Authors:  Rodrigo Machado-Vieira; Giacomo Salvadore; Lobna A Ibrahim; Nancy Diaz-Granados; Carlos A Zarate
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

8.  Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a pilot randomized placebo-controlled trial.

Authors:  Christopher Pittenger; Michael H Bloch; Suzanne Wasylink; Eileen Billingslea; Ryan Simpson; Ewgeni Jakubovski; Ben Kelmendi; Gerard Sanacora; Vladimir Coric
Journal:  J Clin Psychiatry       Date:  2015-08       Impact factor: 4.384

Review 9.  Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders.

Authors:  Gerard Sanacora; Carlos A Zarate; John H Krystal; Husseini K Manji
Journal:  Nat Rev Drug Discov       Date:  2008-05       Impact factor: 84.694

10.  Early parental deprivation in the marmoset monkey produces long-term changes in hippocampal expression of genes involved in synaptic plasticity and implicated in mood disorder.

Authors:  Amanda J Law; Qi Pei; Mary Walker; Helen Gordon-Andrews; Cyndi Shannon Weickert; Joram Feldon; Christopher R Pryce; Paul J Harrison
Journal:  Neuropsychopharmacology       Date:  2008-07-09       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.